XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Significant Agreements (Details Narrative) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Product Liability Contingency [Line Items]          
Agreement description     The Company and Cipla will each be responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”), in addition to which, Cipla will reimburse the Company an amount equal to 10% of aggregate Direct Costs upon the achievement of certain development milestones set forth in the table below, potentially bringing the sharing of Direct Costs to a 50/50 basis. The Company will continue to share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis    
Transaction cost $ 22,000   $ 22,000    
Revenue 1,872 $ 1,069 4,363 $ 4,713  
Deferred revenue, current 1,140   1,140   $ 939
Cipla Agreement [Member] | Cipla Technologies LLC [Member]          
Product Liability Contingency [Line Items]          
Proceeds from related party debt     22,000    
Transaction price     7,400    
Deferred revenue 6,200   6,200    
Deferred revenue, current 1,100   1,100    
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Research and Development Service [Member]          
Product Liability Contingency [Line Items]          
Transaction cost 12,000   12,000    
Revenue 1,900   4,400    
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Irrevocable License [Member]          
Product Liability Contingency [Line Items]          
Transaction cost $ 10,000   $ 10,000